COVID-19 in a patient with SISTEMIC sclerosis: The role of ruxolitinib

COVID-19 in a patient with SISTEMIC sclerosis: The role of ruxolitinib

We describe the case of a 78-year-old Italian woman with COVID-19 affected by Systemic Sclerosis with pulmonary fibrosis treated with Ruxolitinib (Ruxolitinib was provided free of charge by Novartis International AG). We chose Ruxolitinib, as a second-line treatment, after administering a standard t...

Full description

Bibliographic Details
Main Authors:	Claudio Ucciferri, Antonio Auricchio, Stefano Marinari, Jacopo Vecchiet, Katia Falasca
Format:	Article
Language:	English
Published:	SAGE Publishing 2021-09-01
Series:	European Journal of Inflammation
Online Access:	https://doi.org/10.1177/20587392211036813

Similar Items

Clinical characteristics and cardiovascular implications of the dead patients for COVID-19
by: Katia Falasca, et al.
Published: (2021-01-01)

Parameters associated with diagnosis of COVID‐19 in emergency department
by: Claudio Ucciferri, et al.
Published: (2021-09-01)

PIDOTIMOD IN PAUCISYMPTOMATIC SARS-CoV2 INFECTED PATIENTS
by: Claudio Ucciferri, et al.
Published: (2020-06-01)

Cardiac toxicity associated with HCV direct antiviral agents
by: Claudio Ucciferri, et al.
Published: (2018-10-01)

Efficacy of canakinumab in mild or severe COVID‐19 pneumonia
by: Falasca Katia, et al.
Published: (2021-06-01)

Cystatin C and cardiovascular risk in HIV infected patients
by: Vecchiet Jacopo, et al.
Published: (2010-05-01)

Induction with ribavirin in a relapsing patient with chronic HCV hepatitis
by: Claudio Ucciferri, et al.
Published: (2012-05-01)

Induction with ribavirin in a relapsing patient with chronic HCV hepatitis
by: Claudio Ucciferri, et al.

Long term effect of telmisartan in HIV-positive male patients with high blood pressure
by: Claudio Ucciferri, et al.
Published: (2015-11-01)

Long term effect of switching to darunavir/ritonavir in HIV infected patients previously on protease inhibitor therapy
by: Claudio Ucciferri, et al.
Published: (2016-07-01)

USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS
by: Paola Mancino, et al.
Published: (2010-03-01)

USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS
by: Claudio Ucciferri, et al.
Published: (2010-02-01)

Ruxolitinib en COVID-19 grave
by: Marcelo Iastrebner, et al.
Published: (2021-09-01)

Effects of dual renin-angiotensin system blockade on proteinuria in a hypertensive black African HIV-infected patient
by: Claudio Ucciferri, et al.
Published: (2011-04-01)

Late Worsening of COVID-19 Pneumonia: Successful Treatment with Ruxolitinib and Steroid
by: Mauro Betelli, et al.
Published: (2020-10-01)

Effect of Probiotic Supplement on Cytokine Levels in HIV-Infected Individuals: A Preliminary Study
by: Katia Falasca, et al.
Published: (2015-09-01)

Duration of COVID-19: Data from an Italian Cohort and Potential Role for Steroids
by: Damiano D’Ardes, et al.
Published: (2020-08-01)

Predictive factors and prevalence of microalbuminuria in HIV-infected patients: a cross-sectional analysis
by: Katia Falasca, et al.
Published: (2017-07-01)

COVID-19: High-JAKing of the Inflammatory “Flight” by Ruxolitinib to Avoid the Cytokine Storm
by: Cirino Botta, et al.
Published: (2021-01-01)

The impact of homocysteine, B12, and D vitamins levels on functional neurocognitive performance in HIV-positive subjects
by: Katia Falasca, et al.
Published: (2019-02-01)

JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy
by: Alessandro Maria Vannucchi, et al.
Published: (2021-08-01)

Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib
by: Arthur E. Frankel, et al.
Published: (2021-04-01)

Ruxolitinib for the Treatment of Essential Thrombocythemia
by: Arief Gunawan, et al.
Published: (2018-08-01)

Ruxolitinib as an emerging treatment in myelofibrosis
by: Emanuel RM, et al.
Published: (2013-03-01)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
by: Manduzio P
Published: (2017-02-01)

Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
by: Barosi G, et al.
Published: (2015-05-01)

Triggering of Suicidal Erythrocyte Death by Ruxolitinib
by: Marilena Briglia, et al.
Published: (2015-09-01)

Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient
by: Danielle M. Peterson, MD, et al.
Published: (2020-04-01)

Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis
by: Anna Hirano, et al.
Published: (2017-01-01)

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations
by: Blum S, et al.
Published: (2016-09-01)

Ruxolitinib: a targeted treatment option for patients with polycythemia vera
by: Vaddi K, et al.
Published: (2016-05-01)

Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol
by: Enrico Capochiani, et al.
Published: (2020-08-01)

Multiple sclerosis patients and COVID-19
by: Hubert Mado, et al.
Published: (2021-03-01)

Delayed granulomatous eruption of the nose associated with ruxolitinib
by: Margaret Brown, MD, et al.
Published: (2020-07-01)

Ruxolitinib for Therapy of Graft-versus-Host Disease
by: Thomas Neumann, et al.
Published: (2019-01-01)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
by: Ostojic A, et al.
Published: (2012-03-01)

Structural Basis of Inhibition of DCLK1 by Ruxolitinib
by: Dong Man Jang, et al.
Published: (2021-08-01)

Smell and Taste in Severe CoViD-19: Self-Reported vs. Testing
by: Andrea Mazzatenta, et al.
Published: (2020-12-01)

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
by: Leona Dold, et al.
Published: (2021-09-01)

Efficacy of Oral Ruxolitinib in a Patient with Refractory Chronic Spontaneous Urticaria
by: Atsushi Fukunaga, et al.
Published: (2018-07-01)

Cannot write session to /tmp/vufind_sessions/sess_rson4kt65qgv8jhuiq66gr15fc